Effects of the COVID-19 Pandemic on Caregivers of Young Children with Sickle Cell Disease Enrolled in the Engage-HU Trial

Background: Hydroxyurea (HU) is the primary medication used to prevent the significant medical and neurologic morbidities of pediatric sickle cell disease (SCD; HbSS or HbSB0 thalassemia). Despite the benefits of HU, it remains under‐utilized likely due to lack of clinician knowledge/training and ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Hood, Anna M, Hildenbrand, Aimee K, Rebitski, Joanna, Stallworth, Jasmine, Johnson, Yolanda, Gomes, Stacey, Whitacre, Catharine, Mara, Constance A, Shook, Lisa M, Quinn, Charles T., Raphael, Jean L., Yates, Amber M, Badawy, Sherif M., Thompson, Alexis A., Smith-Whitley, Kim, Hartung, Helge, King, Allison A., Creary, Susan E, Bhasin, Neha, Reader, Steven K, Meier, Emily R., Tubman, Venee N., Crosby, Lori E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
901.Health Services Research-Non-Malignant Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701673/
http://dx.doi.org/10.1182/blood-2021-152722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701673/
http://dx.doi.org/10.1182/blood-2021-152722

Ejemplares similares